Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

@article{Mouridsen2007CardiovascularAE,
  title={Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.},
  author={Henning T. Mouridsen and Aparna Keshaviah and Alan S. Coates and Manuela Rabaglio and Monica Castiglione-Gertsch and Zhuoxin Sun and Beat J K Thuerlimann and Louis Mauriac and John F. Forbes and Robert J. Paridaens and Richard D. Gelber and Marco Colleoni and Ian E. Smith and Karen N. Price and Aron Goldhirsch},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 36},
  pages={5715-22}
}
PURPOSE Previous analyses of adjuvant studies of aromatase inhibitors versus tamoxifen, including the Breast International Group (BIG) 1-98 study, have suggested a small numerical excess of cardiac adverse events (AEs) on aromatase inhibitors, a reduction in the incidence of hypercholesterolemia on tamoxifen, and significantly higher incidence of thromboembolic AEs on tamoxifen. The purpose of the present study is to provide detailed updated information on these AEs in BIG 1-98. PATIENTS AND… CONTINUE READING
60 Extracted Citations
20 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 60 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 20 references

Switching to anastrozole versus continued tamoxifen Cardiovascular Adverse Events During Adjuvant Letrozole/Tamoxifen www.jco.org 5721 Copyright © 2007 by the American Society of Clinical Oncology

  • F Boccardo, A Rubagotti, M Puntoni
  • All rights reserved
  • 2007

Similar Papers

Loading similar papers…